Medication info
Polmindapaserbongjeong 10/1000 milligrams

Polmindapaserbongjeong 10/1000 milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Noksibja Co., Ltd.
Appearance
Yellow, biconvex, oval, sustained-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP x 5)]
Approval status
Active

MFDS item code 202300239 · Approved 2023.01.12 · Insurance code 643606500

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may affect glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Ingredients

Manufacturer
Noksibja Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes when used in conjunction with dietary and exercise therapy. In particular, combining dapagliflozin and metformin can provide more effective blood sugar management. Additionally, caution is required when using this medication in patients with existing cardiovascular disease or risk factors who do not achieve adequate blood sugar control, and it is important to refer to relevant clinical trial information. This medication can assist in managing both blood sugar control and cardiovascular health simultaneously.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may affect glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Precautions

This medication can very rarely cause a serious condition called lactic acidosis, so caution is required regarding this. When used with other diabetes medications, there is a risk of hypoglycemia, so caution is advised. It should not be administered to patients with moderate to severe renal impairment or those with dehydration, severe infections, or cardiovascular issues. Pregnant or nursing women and patients with genetic issues such as lactose intolerance should not use this medication. Patients with reduced fluid volume or renal impairment should exercise caution when using this medication, as there may be a risk of blood pressure reduction or deterioration of kidney function, requiring regular monitoring. During treatment with this medication, side effects such as genital infections, urinary tract infections, hypoglycemia, reduced fluid volume, renal dysfunction, etc., may occur, so if symptoms arise, it is crucial to consult healthcare professionals immediately. Furthermore, this medication can lower vitamin B12 levels, so checking vitamin B12 status during long-term use is advised. Excessive alcohol consumption may increase the risk of side effects from this medication. Before surgery or diagnostic tests using iodinated contrast media, this medication should be stopped for a certain period, and it should be resumed only after confirming normal kidney function. Elderly patients are at increased risk of kidney function deterioration and reduced fluid volume, thus requiring dosage adjustments and regular kidney function assessments when using this medication. Caution is also advised for dizziness when operating vehicles or machinery during treatment with this medication. Finally, this medication should be kept out of reach of children and stored in its original container for safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • malignant lung neoplasms
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland masses
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periartritis
  • tenosynovitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius to ensure the medication's effectiveness.

Appearance and packaging

Appearance

Yellow, biconvex, oval, sustained-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP x 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.